PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550561
PUBLISHER: Coherent Market Insights | PRODUCT CODE: 1550561
Global small molecule drug discovery market is estimated to be valued at USD 56.10 Bn in 2024 and is expected to reach USD 100.01 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 8.6% from 2024 to 2031.
Report Coverage | Report Details | ||
---|---|---|---|
Base Year: | 2023 | Market Size in 2024: | US$ 56.10 Bn |
Historical Data for: | 2019 to 2023 | Forecast Period: | 2024 to 2031 |
Forecast Period 2024 to 2031 CAGR: | 8.60% | 2031 Value Projection: | US$ 100.01 Bn |
Small molecule drugs have advantages over large molecule drugs such as higher oral bioavailability and better tissue penetration. These can be administered via various routes including oral, intravenous and others. Growing investment in R&D activities by pharmaceutical and biotech companies coupled with rising demand for generics can drive the market growth. However, high attrition rates during clinical trials can hamper the market growth. Several startups also leverage technologies such as artificial intelligence and machine learning to enhance the drug discovery process and reduce failure rates.
Global small molecule drug discovery market growth is driven by rising pharmaceutical R&D spending, increasing demand for generic drugs, and growth of contract research and manufacturing services industries. However, high clinical failure rates of drug candidates and stringent regulations can hamper the market growth. Growing application of AI and machine learning in drug development offers new opportunities for the market players. Pharma companies are increasingly adopting such technologies to speed up the discovery process and optimize molecular designs. This can lower attrition rates. North America dominates the market currently, owing to presence of major players and high healthcare expenditure. Asia Pacific is anticipated to emerge as the fastest growing market in the near future.
This report provides in-depth analysis of the global small molecule drug discovery market, and provides market size (USD Billion) and compound annual growth rate (CAGR%) for the forecast period (2024-2031), considering 2023 as the base year
It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
It profiles key players in the global small molecule drug discovery market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
Key companies covered as a part of this study include Pfizer, Bristol-Myers Squibb Company, Merck, Agilent Technologies, AstraZeneca, Boehringer Ingelheim, Charles River Laboratories
Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
Global small molecule drug discovery market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global small molecule drug discovery market
Detailed Segmentation-